Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histone deacetylase inhibitor that differs from approved...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Ribrag, Vincent, Kim, Won Seog, Bouabdallah, Reda, Lim, Soon Thye, Coiffier, Bertrand, Illes, Arpad, Lemieux, Bernard, Dyer, Martin J. S., Offner, Fritz, Felloussi, Zakia, Kloos, Ioana, Luan, Ying, Vezan, Remus, Graef, Thorsten, Morschhauser, Franck
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2017
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5477609/
https://ncbi.nlm.nih.gov/pubmed/28126962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.154377
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars